Lemieux Pierre
Gene Therapy Department, Supratek Pharma Inc., Laval, Quebec, Canada.
Expert Rev Vaccines. 2002 Jun;1(1):85-93. doi: 10.1586/14760584.1.1.85.
The latest clinical data obtained with DNA vaccines against HIV and malaria have shown promise, but it is clear that when DNA vaccines are compared with other vaccine vector delivery systems, there is still room for improvement. Further development is more than possible, based on the wealth of information accumulating on methods and approaches to increase immunogenicity of DNA vaccines. Thus, the goal of this review is to summarize some of the latest technological advances to increase immunogenicity of DNA vaccines administered by the im. and id. routes. By means of examples, the review will be intended to focus only on recent developments reported in the last 2 years and likely to go towards the improvement of mucosal, humoral and cellular immune responses mostly against cancer and infectious disease antigens.
针对HIV和疟疾的DNA疫苗所获得的最新临床数据已显示出前景，但很明显，当将DNA疫苗与其他疫苗载体递送系统进行比较时，仍有改进的空间。基于在提高DNA疫苗免疫原性的方法和途径方面积累的丰富信息，进一步的发展是完全有可能的。因此，本综述的目的是总结一些最新的技术进展，以提高通过肌内注射和皮内注射途径给药的DNA疫苗的免疫原性。通过实例，本综述将仅关注过去两年报道的最新进展，这些进展可能有助于改善主要针对癌症和传染病抗原的黏膜、体液和细胞免疫反应。
